Chronic Histological Damage in Early Indication Biopsies Is an Independent Risk Factor for Late Renal Allograft Failure

American Journal of Transplantation

Volumn 13, Issue 1, 2013, Pages 86-99

  Naesens, M ^a,b   Kuypers, D R J ^a,b   De Vusser, K ^a,b   Vanrenterghem, Y ^a,b   Evenepoel, P ^a,b   Claes, K ^a,b   Bammens, B ^a,b   Meijers, B ^a,b   Lerut, E ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KU ^*  (Belgium)

^c DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

Author keywords

Death censored graft survival; histology; kidney transplantation; long term outcome

Indexed keywords

ADULT; ARTICLE; BANFF CLASSIFICATION; BIOPSY TECHNIQUE; COHORT ANALYSIS; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYALINE DEGENERATION; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; RISK FACTOR; TREATMENT INDICATION;

ADULT; BIOPSY; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84871716526     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04304.x     Document Type: Article

References (36)

1. El-Zoghby ZM, Stegall MD, Lager DJ, et al.. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
2. Sellares J, De Freitas DG, Mengel M, et al.. Inflammation lesions in kidney transplant biopsies: Association with survival is due to the underlying diseases. Am J Transplant 2011; 11: 489-499.
3. Gaston RS, Cecka JM, Kasiske BL, et al.. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
4. Loupy A, Hill GS, Jordan SC,. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012; 8: 348-357.
5. Sellares J, de Freitas DG, Mengel M, et al.. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
6. Yilmaz S, Tomlanovich S, Mathew T, et al.. Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies. J Am Soc Nephrol 2003; 14: 773-779.
7. Legendre C, Thervet E, Skhiri H, et al.. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998; 65: 1506-1509.
8. Kuypers DR, Chapman JR, O'Connell PJ, Allen RD, Nankivell BJ,. Predictors of renal transplant histology at three months. Transplantation 1999; 67: 1222-1230.
9. Solez K, Colvin RB, Racusen LC, et al.. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
10. Nankivell BJ, Richard J, Borrows RJ, et al.. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
11. Naesens M, Lerut E, de Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DR,. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 2009; 20: 2468-2480.
12. Cosio FG, Grande JP, Larson TS, et al.. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005; 5: 1130-1136.
13. Nankivell BJ, Fenton-Lee CA, Kuypers DR, et al.. Effects of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515-523.
14. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD,. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464-2472.
15. Moreso F, Ibernon M, Goma M, et al.. Subclinical Rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747-752.
16. Sis B, Mengel M, Haas M, et al.. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
17. Mengel M, Sis B, Haas M, et al.. Banff 2011 meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
18. Sis B, Einecke G, Chang J, et al.. Cluster analysis of lesions in nonselected kidney transplant biopsies: Microcirculation changes, tubulointerstitial inflammation and scarring. Am J Transplant 2010; 10: 421-430.
19. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB,. Strategies to improve long-term outcomes after renal transplantation. New Engl J Med 2002; 346: 580-590.
20. Halloran PF, Melk A, Barth C,. Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J AmSocNephrol 1999; 10: 167-181.
21. Naesens M, Kuypers DR, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
22. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD,. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987-1997.
23. Naesens M, Khatri P, Li L, et al.. Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. Kidney Int 2011; 80: 1364-1376.
24. Nankivell BJ, Chapman JR,. Chronic allograft nephropathy: Current concepts and future directions. Transplantation 2006; 81: 643-654.
25. Harris RC, Neilson EG,. Toward a unified theory of renal progression. Annu Rev Med 2006; 57: 365-380.
26. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Feehally J, et al.. The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.
27. Berden AE, Jones RB, Erasmus DD, et al.. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 2012; 23: 313-321.
28. Halloran PF, Homik J, Goes N, et al.. The "injury response": A concept linking nonspecific rejection, and long-term transplant outcomes. Transplant Proc 1997; 29: 79-81.
29. de Fijter JW, Mallat MJK, Doxiadis IIN, et al.. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001; 12: 1538-1546.
30. Schold JD, Rehman S, Kayle LK, Magliocca J, Srinivas TR, Meier-Kriesche HU,. Treatment for BK virus: Incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009; 22: 626-634.
31. Suri DL, Tomlanovich SJ, Olson JL, Meyer TW,. Transplant glomerulopathy as a cause of late graft loss. Am J Kidney Dis 2000; 35: 674-680.
32. Lerut E, Naesens M, Kuypers DR, Vanrenterghem Y, Van Damme B,. Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation 2007; 83: 1416-1422.
33. Sis B, Campbell PM, Mueller T, et al.. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743-1752.
34. Haas M,. Pathologic features of antibody-mediated rejection in renal allografts: An expanding spectrum. Curr Opin Nephrol Hypertens 2012; 21: 264-271.
35. Halloran PF, de Freitas DG, Sellarés J,. Understanding why T cells are found in troubled transplants: A response to Professor Randhawa. Am J Transplant 2012; 12: 1961-1961.
36. Stegall MD, Park WD, Larson TS, et al.. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11: 698-707.